VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT ID: NCT00063713
Last Updated: 2008-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
152 participants
INTERVENTIONAL
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00257114
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
NCT01090921
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
NCT00210327
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
NCT00715208
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
NCT00636792
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VELCADE TM (bortezomib) for Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of mantle cell lymphoma
* Documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. At least one of those regimens must have included an anthracycline or mitoxantrone. Relapsed or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions.
* At least 1 measurable or evaluable site of disease
* Voluntary consent
Exclusion Criteria
* Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug
* Radiation therapy within 3 weeks before the first dose of study drug
* Major surgery with 2 weeks before the first dose of study drug
* Rituximab, Campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug
* Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug
* History of allergic reactions to boron or mannitol compounds
* Diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug
* Active systemic infection requiring treatment
* Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile)
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Alta Bates Medical Center
Berkeley, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Loma Linda Cancer Research Institute
Loma Linda, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of Colorado Cancer
Denver, Colorado, United States
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
The Rush Cancer Center
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
University of Iowa Hospital Division
Iowa City, Iowa, United States
North Memorial Hospital
Robbinsdale, Minnesota, United States
Onc/Hem Associates of Kansas City
Kansas City, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Beth Israel Medical Center
New York, New York, United States
St Lukes-Roosevelt Hospital
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
New York Hospital Cornell Medical Center
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Wake Forest, University health Sciences/Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Cancer Care Associates
Oklahoma City, Oklahoma, United States
Cancer Care Associates
Tulsa, Oklahoma, United States
Oregon Health Science University
Portland, Oregon, United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
University Hospital-Madison Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M34103-053
Identifier Type: -
Identifier Source: org_study_id
NCT00084851
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.